From ChildrensHomeDefense.org…
Pfizer announced Tuesday projected combined sales of its COVID vaccine and antiviral drug Paxlovid should top $54 billion in 2022, constituting more than 50% of the company’s expected revenues of about $100 billion.
The drugmaker predicted slightly lower 2022 revenues ($32 billion) for the vaccine compared to 2021, but increased revenues ($22 billion) from Paxlovid, the company’s COVID-19 pill.
Pfizer stock today “dropped sharply after the company’s 2022 sales guidance appeared to fall short of expectations,” Barron’s reported.
According to Barron’s:
“The antiviral sales guidance met the consensus estimate according to FactSet, but the Covid vaccine guidance fell short by $2.8 billion. The FactSet estimate for Pfizer’s overall revenue for 2022 was $103.2 billion, around $3 billion above the midpoint of Pfizer’s guidance range.”
